28333018|t|Nationwide, Multicenter, Retrospective Study on High-Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer
28333018|a|To present, analyze, and discuss results of a nationwide, multicenter, retrospective study on high-dose-rate brachytherapy (HDR-BT) as monotherapy for low-, intermediate-, and high-risk prostate cancer. From 1995 through 2013, 524 patients, 73 (14%) with low-risk, 207 (40%) with intermediate-risk, and 244 (47%) with high-risk prostate cancer, were treated with HDR-BT as monotherapy at 5 institutions in Japan. Dose fractionations were 27 Gy/2 fractions for 69 patients (13%), 45.5 Gy/7 fractions for 168 (32%), 49 Gy/7 fractions for 149 (28%), 54 Gy/9 fractions for 130 (25%), and others for 8 (2%). Of these patients, 156 (30%) did not receive androgen deprivation therapy, and 202 patients (39%) did receive androgen deprivation therapy <1 year, 112 (21%) for 1-3 years, and 54 (10%) for >3 years. Median follow-up time was 5.9 years (range, 0.4-18.1 years), with a minimum of 2 years for surviving patients. After 5 years, respective actuarial rates of no biochemical evidence of disease, overall survival, cause -specific survival, and metastasis - free survival for all patients were 92%, 97%, 99%, and 94%. For low / intermediate / high-risk patients, the 5- year no biochemical evidence of disease rates were 95%/94%/89%, the 5- year overall survival rates were 98%/98%/94%, the 5- year cause -specific survival rates were 98%/100%/98%, and the 5- year metastasis - free survival rates were 98%/95%/90%, respectively. The cumulative incidence of late grade 2 to 3 genitourinary toxicity at 5 years was 19%, and that of late grade 3 was 1%. The corresponding incidences of gastrointestinal toxicity were 3% and 0% (0.2%). No grade 4 or 5 of either type of toxicity was detected. The findings of this nationwide, multicenter, retrospective study demonstrate that HDR-BT as monotherapy was safe and effective for all patients with low-, intermediate-, and high-risk prostate cancer.
28333018	0	10	Nationwide	T082	C1254362
28333018	12	23	Multicenter	T062	C1096776
28333018	25	44	Retrospective Study	T062	C0035363
28333018	48	76	High-Dose-Rate Brachytherapy	T061	C0454270
28333018	80	91	Monotherapy	T061	C0087111
28333018	96	111	Prostate Cancer	T191	C0376358
28333018	124	131	analyze	T169	C1524024
28333018	158	168	nationwide	T082	C1254362
28333018	170	181	multicenter	T062	C1096776
28333018	183	202	retrospective study	T062	C0035363
28333018	206	234	high-dose-rate brachytherapy	T061	C0454270
28333018	236	242	HDR-BT	T061	C0454270
28333018	247	258	monotherapy	T061	C0087111
28333018	263	267	low-	T081	C3538919
28333018	269	282	intermediate-	T033	C3640764
28333018	288	297	high-risk	T033	C0332167
28333018	298	313	prostate cancer	T191	C0376358
28333018	343	351	patients	T101	C0030705
28333018	367	375	low-risk	T081	C3538919
28333018	392	409	intermediate-risk	T033	C3640764
28333018	430	439	high-risk	T033	C0332167
28333018	440	455	prostate cancer	T191	C0376358
28333018	462	469	treated	T169	C1522326
28333018	475	481	HDR-BT	T061	C0454270
28333018	485	496	monotherapy	T061	C0087111
28333018	502	514	institutions	T078	C1272753
28333018	518	523	Japan	T083	C0022341
28333018	525	544	Dose fractionations	T061	C0524811
28333018	558	567	fractions	T081	C1264633
28333018	575	583	patients	T101	C0030705
28333018	601	610	fractions	T081	C1264633
28333018	634	643	fractions	T081	C1264633
28333018	667	676	fractions	T081	C1264633
28333018	724	732	patients	T101	C0030705
28333018	752	759	receive	T080	C1514756
28333018	760	788	androgen deprivation therapy	T061	C0279492
28333018	798	806	patients	T101	C0030705
28333018	817	824	receive	T080	C1514756
28333018	825	853	androgen deprivation therapy	T061	C0279492
28333018	857	861	year	T079	C0439234
28333018	881	886	years	T079	C0439234
28333018	908	913	years	T079	C0439234
28333018	915	931	Median follow-up	T058	C1522577
28333018	932	936	time	T079	C0040223
28333018	945	950	years	T079	C0439234
28333018	968	973	years	T079	C0439234
28333018	996	1001	years	T079	C0439234
28333018	1006	1024	surviving patients	T101	C0030705
28333018	1034	1039	years	T079	C0439234
28333018	1052	1067	actuarial rates	T081	C1521828
28333018	1071	1073	no	T033	C1513916
28333018	1074	1085	biochemical	T169	C0205474
28333018	1086	1094	evidence	T078	C3887511
28333018	1098	1105	disease	T047	C0012634
28333018	1107	1114	overall	T080	C1561607
28333018	1115	1123	survival	T169	C0220921
28333018	1125	1130	cause	T169	C0015127
28333018	1141	1149	survival	T169	C0220921
28333018	1155	1165	metastasis	T046	C4255448
28333018	1168	1172	free	T169	C0332296
28333018	1173	1181	survival	T169	C0220921
28333018	1190	1198	patients	T101	C0030705
28333018	1232	1235	low	T081	C3538919
28333018	1238	1250	intermediate	T033	C3640764
28333018	1253	1262	high-risk	T033	C0332167
28333018	1263	1271	patients	T101	C0030705
28333018	1280	1284	year	T079	C0439234
28333018	1285	1287	no	T033	C1513916
28333018	1288	1299	biochemical	T169	C0205474
28333018	1300	1308	evidence	T078	C3887511
28333018	1312	1325	disease rates	T081	C0026538
28333018	1351	1355	year	T079	C0439234
28333018	1356	1363	overall	T080	C1561607
28333018	1364	1378	survival rates	T081	C0038954
28333018	1404	1408	year	T079	C0439234
28333018	1409	1414	cause	T169	C0015127
28333018	1425	1439	survival rates	T081	C0038954
28333018	1470	1474	year	T079	C0439234
28333018	1475	1485	metastasis	T046	C4255448
28333018	1488	1492	free	T169	C0332296
28333018	1493	1507	survival rates	T081	C0038954
28333018	1544	1554	cumulative	T080	C1511559
28333018	1555	1564	incidence	T081	C0021149
28333018	1568	1572	late	T079	C0205087
28333018	1573	1578	grade	T185	C0441800
28333018	1586	1599	genitourinary	T029	C3887515
28333018	1600	1608	toxicity	T037	C0600688
28333018	1614	1619	years	T079	C0439234
28333018	1641	1645	late	T079	C0205087
28333018	1646	1651	grade	T185	C0441800
28333018	1680	1690	incidences	T081	C0021149
28333018	1694	1710	gastrointestinal	T082	C0521362
28333018	1711	1719	toxicity	T037	C0600688
28333018	1743	1745	No	T033	C1513916
28333018	1746	1751	grade	T185	C0441800
28333018	1769	1773	type	T080	C0332307
28333018	1777	1785	toxicity	T037	C0600688
28333018	1790	1798	detected	T033	C0442726
28333018	1804	1812	findings	T169	C2607943
28333018	1821	1831	nationwide	T082	C1254362
28333018	1833	1844	multicenter	T062	C1096776
28333018	1846	1865	retrospective study	T062	C0035363
28333018	1883	1889	HDR-BT	T061	C0454270
28333018	1893	1904	monotherapy	T061	C0087111
28333018	1936	1944	patients	T101	C0030705
28333018	1950	1954	low-	T081	C3538919
28333018	1956	1969	intermediate-	T033	C3640764
28333018	1975	1984	high-risk	T033	C0332167
28333018	1985	2000	prostate cancer	T191	C0376358